| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Beà, Aida |
| dc.contributor.author | Valero J.G. |
| dc.contributor.author | Irazoki, Andrea |
| dc.contributor.author | Lana, Carlos |
| dc.contributor.author | López-Lluch, Guillermo |
| dc.contributor.author | Portero-Otin, Manuel |
| dc.contributor.author | Inserte Igual, Javier |
| dc.contributor.author | Ruiz Meana, Marisol |
| dc.date.accessioned | 2022-07-19T09:49:15Z |
| dc.date.available | 2022-07-19T09:49:15Z |
| dc.date.issued | 2022-05 |
| dc.identifier.citation | Beà A, Valero JG, Irazoki A, Lana C, López-Lluch G, Portero-Otín M, et al. Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway. FEBS J. 2022;289(9):2540–61. |
| dc.identifier.issn | 1742-4658 |
| dc.identifier.uri | https://hdl.handle.net/11351/7812 |
| dc.description | Cardiac fibroblast; Cellular respiration; Survival |
| dc.description.abstract | Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it. |
| dc.language.iso | eng |
| dc.publisher | Wiley |
| dc.relation.ispartofseries | The FEBS Journal;289(9) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Sistema cardiovascular - Malalties |
| dc.subject | Fibroblasts |
| dc.subject.mesh | Cardiovascular Diseases |
| dc.title | Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1111/febs.16283 |
| dc.subject.decs | enfermedades cardiovasculares |
| dc.relation.publishversion | https://doi.org/10.1111/febs.16283 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Beà A, Lana C] Cell Signaling & Apoptosis Group, Institut de Recerca Biomedica de Lleida (IRBLleida), Universitat de Lleida, Spain. [Valero JG] Department of Hematology-Oncology, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigacion Biomédica en Red-Oncología (CIBERONC), Barcelona, Spain. [Irazoki A] Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat de Barcelona, Spain. [López-Lluch G] Andalusian Center of Developmental Biology, Pablo de Olavide University, Sevilla, Spain. Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Sevilla, Spain. [Portero-Otín M] Department of Experimental Medicine, IRBLleida, University of Lleida, Lleida, Spain. [Inserte J, Ruiz-Meana M] Laboratori de Cardiologia Experimental, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Spain. Centro de Investigación Biomédica en Red-CV (CIBER-CV), Barcelona, Spain |
| dc.identifier.pmid | 34796659 |
| dc.identifier.wos | 000723010200001 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01196 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |